Tags : Synthetic Lethality Cancer


GSK Signs a Synthetic Lethality Cancer Agreement with Ideaya for

Shots: Ideaya to receive ~$100M as upfront in cash, $20M as equity investment, $50M in cash as option exercise fee for the MAT2A program and is eligible to receive preclinical, clinical, and commercial milestones The collaboration includes Ideaya’s synthetic lethality programs MAT2A, Pol Theta, and Werner Helicase programs, which are projected to reach clinical trials […]Read More